149 related articles for article (PubMed ID: 35116526)
1. RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.
He Y; Tao W; Ji D; Lu W; Xiong Y; Chen G
Transl Cancer Res; 2021 May; 10(5):2044-2054. PubMed ID: 35116526
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
Huang BT; Zeng QC; Yu J; Xiao Z; Li BS; Zhang CL; Ji HB
J Cancer Res Clin Oncol; 2012 Jan; 138(1):125-32. PubMed ID: 22057732
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
5. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
Hu C; Deng C; Zou W; Zhang G; Wang J
Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
[TBL] [Abstract][Full Text] [Related]
6. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
LaCasce AS; Vandergrift JL; Rodriguez MA; Abel GA; Crosby AL; Czuczman MS; Nademanee AP; Blayney DW; Gordon LI; Millenson M; Vanderplas A; Lepisto EM; Zelenetz AD; Niland J; Friedberg JW
Blood; 2012 Mar; 119(9):2093-9. PubMed ID: 22234679
[TBL] [Abstract][Full Text] [Related]
7. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials.
Intzes S; Symeonidou M; Zagoridis K; Pentidou A; Bezirgianidou Z; Papoutselis M; Misidou C; Roumpakis C; Spanoudaki A; Liapis K; Spanoudakis E
Ann Hematol; 2024 May; 103(5):1623-1633. PubMed ID: 38191715
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP.
Halahleh K; Yaseen A; Muradi I; Al-Ibraheem A; Sultan I; Ma'koseh M
J Blood Med; 2023; 14():147-157. PubMed ID: 36846350
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Olszewski AJ; Butera JN; Reagan JL; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.
Ohnishi K; Ohmachi K; Ando K; Yamamoto K; Ito T; Tanimoto M; Ohbayashi K; Ohyashiki K; Tsukasaki K; Naito K; Suzuki T; Ono T; Miyamura K; Kagami Y; Kinoshita T; Hotta T; Ogura M
J Clin Exp Hematop; 2021 Sep; 61(3):162-167. PubMed ID: 34193755
[TBL] [Abstract][Full Text] [Related]
12. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
Odejide OO; Cronin AM; Davidoff AJ; LaCasce AS; Abel GA
Leuk Lymphoma; 2015 Mar; 56(3):716-24. PubMed ID: 24913508
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Witzig TE; Hong F; Micallef IN; Gascoyne RD; Dogan A; Wagner H; Kahl BS; Advani RH; Horning SJ
Br J Haematol; 2015 Sep; 170(5):679-86. PubMed ID: 25974212
[TBL] [Abstract][Full Text] [Related]
15. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
17. [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
Xiong W; Yi S; Li H; Liu H; Li Z; Lü R; Liu W; Zou D; Qiu L
Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3593-7. PubMed ID: 26813371
[TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
McBride NC; Cavenagh JD; Ward MC; Grant I; Schey S; Gray A; Hughes A; Mills MJ; Cervi P; Newland AC; Kelsey SM
Leuk Lymphoma; 2001 Jun; 42(1-2):89-98. PubMed ID: 11699226
[TBL] [Abstract][Full Text] [Related]
19. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
Cohen JB; Geyer SM; Lozanski G; Zhao W; Heerema NA; Hall NC; Nagar VA; Hemminger JA; Jones JA; Porcu P; Christian BA; Baiocchi RA; Maddocks KJ; Flynn JM; Devine SM; Blum KA
Cancer; 2014 Jun; 120(11):1677-85. PubMed ID: 24578014
[TBL] [Abstract][Full Text] [Related]
20. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.
Zhou M; Wang J; Ouyang J; Xu JY; Chen B; Zhang QG; Zhou RF; Yang YG; Shao XY; Xu Y; Chen YM; Fan XS; Wu HY
Tumour Biol; 2014 Jul; 35(7):6757-62. PubMed ID: 24719189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
